Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Larry Greenbaum, MD, Christophe M. Legendre, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Frank Eitner, MD, Yahsou Delmas, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 2084.

https://doi.org/10.1182/blood.V120.21.2084.2084

Published: 2012

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Samhar I. Al-Akash, Timothy H. J. Goodship, MD, Richard J. H. Smith, MD, Christophe M. Legendre, MD, Christoph Licht, MD, Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Veronique Frémeaux-Bacchi, PhD, Chantal Loirat, MD

Blood (2012) 120 (21): 2085.

https://doi.org/10.1182/blood.V120.21.2085.2085

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

Luca A. Lotta, Haifeng M. Wu, Ian J. Mackie, Marina Noris, Agnes Veyradier, Marie A. Scully, Giuseppe Remuzzi, Paul Coppo, Ri Liesner, Roberta Donadelli, Chantal Loirat, Richard A. Gibbs, April Horne, Shangbin Yang, Isabella Garagiola, Khaled M. Musallam, Flora Peyvandi

Blood (2012) 120 (2): 440–448.

https://doi.org/10.1182/blood-2012-01-403113

Published: 2012

Includes: Supplemental data

Journal Articles

Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype

Luca A Lotta, Haifeng M Wu, Marie A Scully, Marina Noris, Agnes Veyradier, Ian J Mackie, PhD FRCPath, Giuseppe Remuzzi, Paul Coppo, Ri Liesner, Roberta Donadelli, Chantal Loirat, MD, Richard A Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi

Blood (2011) 118 (21): 2219.

https://doi.org/10.1182/blood.V118.21.2219.2219

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Larry Greenbaum, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Osama Gaber, MD, Frank Eitner, MD, Yahsou Delmas, MD, Chantal Loirat, MD, Camille L Bedrosian, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 193.

https://doi.org/10.1182/blood.V118.21.193.193

Published: 2011

Journal Articles

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Petra Muus, MD, PhD, Christoph Licht, MD, Tim H. J. Goodship, MD, Larry Greenbaum, MD, Camille L Bedrosian, MD, Chantal Loirat, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 4772.

https://doi.org/10.1182/blood.V118.21.4772.4772

Published: 2011

Journal Articles

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

Lubka T. Roumenina, Mathieu Jablonski, Christophe Hue, Jacques Blouin, Jordan D. Dimitrov, Marie-Agnes Dragon-Durey, Mathieu Cayla, Wolf H. Fridman, Marie-Alice Macher, David Ribes, Luc Moulonguet, Lionel Rostaing, Simon C. Satchell, Peter W. Mathieson, Catherine Sautes-Fridman, Chantal Loirat, Catherine H. Regnier, Lise Halbwachs-Mecarelli, Veronique Fremeaux-Bacchi

Blood (2009) 114 (13): 2837–2845.

https://doi.org/10.1182/blood-2009-01-197640

Published: 2009

Includes: Supplemental data

Journal Articles

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

Blood (2008) 112 (13): 4948–4952.

https://doi.org/10.1182/blood-2008-01-133702

Published: 2008

Includes: Supplemental data

NARROW

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only